EANS-Adhoc: SYGNIS Pharma AG SYGNIS Pharma AG announces changes in Management
Board
--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
C.E.O. Interviews
17.10.2012
SYGNIS Pharma AG announces changes in Management Board
Heidelberg, 17 October 2012 - SYGNIS Pharma AG
(Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard) announced today that
Dr. Frank Rathgeb, Co-CEO/CMO will resign from his office in the Management
Board of the company by October 31, 2012 in mutual agreement with the
Supervisory Board.
The retirement of Dr. Rathgeb takes place in context with the intended
strategic reorientation of the company after the planned contribution of all
shares of X-Pol Biotech, S.L., into SYGNIS Pharma AG, with the consequence
that drug development and research in the field of therapeutics will no
longer be in the core focus of the company.
Ende of adhoc
Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de
end of announcement euro adhoc
--------------------------------------------------------------------------------
issuer: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
Stuttgart, regulated dealing/prime standard: Frankfurt
language: English